Literature DB >> 27045427

Minimally invasive periodontal therapy for general practitioners.

Mark I Ryder, Gary C Armitage.   

Abstract

There remains a high prevalence of mild-to-moderate forms of periodontal diseases in both developed and developing countries. Although many periodontal specialty practices currently place strong emphasis on implant surgery, periodontal plastic surgery and esthetics, general dentists and hygienists have often assumed more responsibility than periodontal specialty practices for the diagnosis, treatment, assessment and maintenance, and possible referral, of their patients. To address these current trends and challenges, this volume of Periodontology 2000 presents a series of topics on the basic biological principles of periodontal disease, as well as on approaches to diagnosis, treatment planning and treatment, in what is called 'conservative' or 'noninvasive' periodontal therapy. These topics include risk assessment of the periodontal condition; reduction, elimination and/or control of etiologies and risk factors, including mechanical, antimicrobial and host-modulation approaches; considerations for evaluation of clinical outcomes based on treatment approaches; and selected topics in laser therapy, halitosis and gingival recession.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2016        PMID: 27045427     DOI: 10.1111/prd.12132

Source DB:  PubMed          Journal:  Periodontol 2000        ISSN: 0906-6713            Impact factor:   7.589


  1 in total

1.  Antimicrobial photodynamic chemotherapy mediated by PapaMBlue on chronic periodontal disease: Study protocol for a randomized, blind, controlled trial.

Authors:  Giuliana Giovinazzo Anselmo; Ana Carolina Alves Camargo Tortamano; Marcela Letícia Leal Gonçalves; Adriana Leal-Rossi; Bianca Aparecida Godoy-Miranda; Márcia Regina Cabral Oliveira; Pedro Henrique Cabral Oliveira; Carol Brandt Alves; Sandra Kalil Bussadori; Renato Araujo Prates
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.